Conferences - Results from #10120

EAU 2017: State-of-the-art Lecture: EAU Guidelines on mCRPC – An Update March 27, 2017

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? No March 27, 2017

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? Yes March 27, 2017

EAU 2017: State-of-the-art lecture Hereditary Prostate Cancer March 27, 2017

EAU 2017: Active Surveillance for 3+4=7 Prostate Cancer - Pro March 27, 2017

EAU 2017: Lessons from the ProtecT trial March 27, 2017

EAU 2017: Con – mpMRI targeted biopsies are sufficient March 27, 2017

EAU 2017: Con – Prostate Cancer Screening: Time to change recommendations for PSA testing March 27, 2017

EAU 2017: State-of-the-art Lecture: How will Immunotherapy Change the Treatment Paradigm? March 27, 2017

EAU 2017: State-of-the-art Lecture: Is There Still a Role for Chemotherapy? March 27, 2017

EAU 2017: Lymph node dissection is not associated with increased 30-day complication among patients undergoing radical nephrectomy for renal cell carcinoma: a propensity-score based analysis March 27, 2017

EAU 2017: Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease? March 27, 2017

EAU 2017: Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT) March 26, 2017

EAU 2017: Familial and genetic factors: New SNPs and panels March 26, 2017

EAU 2017: Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling March 26, 2017

EAU 2017: State-of-the-art Lecture Immunotherapy: Open Questions and Trials March 26, 2017

State-of-the-art Lecture Immunotherapy: Impact from Surgeon’s Point of View March 26, 2017

EAU 2017: State-of-the-art Lecture Immunotherapy: Impact from Oncologist’s Point of View March 26, 2017

EAU 2017: A nomogram for prediction of local cancer recurrence after primary prostate cryoablation March 26, 2017

EAU 2017: First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer March 26, 2017

Page 507 of 616